{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:12:05Z","timestamp":1778685125803,"version":"3.51.4"},"reference-count":29,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome","award":["B9R04400"],"award-info":[{"award-number":["B9R04400"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>There is a deficit between existing levels of paediatric clinical research in low- and middle-income countries (LMICs) and what is warranted based on the disease burden in children in these countries. Lack of market protections, low ability to pay and cost-based pricing are key commercial barriers to industry-funded paediatric research and access to paediatric formulations of therapeutics in LMICs. Individual patient data meta-analysis (IPD-MA) taking advantage of existing clinical trials, enabled by data sharing, is one potential tool to bridge the research gap in a cost-effective and efficient way. Recent IPD-MAs of paediatric antimalarial drug safety and efficacy enabled by the WorldWide Antimalarial Resistance Network (WWARN), part of the Infectious Diseases Data Observatory (IDDO), demonstrate the feasibility of this approach.<\/jats:p>","DOI":"10.1136\/bmjopen-2025-100150","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:16Z","timestamp":1778682316000},"page":"e100150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Individual patient data meta-analysis: a cost-effective and efficient tool to advance paediatric research in low- and middle-income countries"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1657-1089","authenticated-orcid":false,"given":"Frederick","family":"McElwee","sequence":"first","affiliation":[{"name":"Economics of Population Health Research Centre, University of Oxford, Oxford, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Farlow","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[{"name":"WorldWide Antimalarial Resistance Network (WWARN), Oxford, England, UK"},{"name":"Infectious Diseases Data Observatory (IDDO), Oxford, England, UK"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051307251272000_16.5.e100150.1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jpc.13537","article-title":"Disease burden-research match? Registered trials in child health from low- and middle-income and high-income countries","volume":"53","author":"Joseph","year":"2017","journal-title":"J Paediatr Child Health"},{"key":"2026051307251272000_16.5.e100150.2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jclinepi.2015.06.021","article-title":"Different treatment benefits were estimated by clinical trials performed in adults compared with those performed in children","volume":"68","author":"Janiaud","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2026051307251272000_16.5.e100150.3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bcp.15148","article-title":"Twice neglected? Neglected diseases in neglected populations","volume":"88","author":"Weld","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"2026051307251272000_16.5.e100150.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4573"},{"key":"2026051307251272000_16.5.e100150.5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical trials in children","volume":"79","author":"Joseph","year":"2015","journal-title":"Brit J Clinical Pharma"},{"key":"2026051307251272000_16.5.e100150.6","doi-asserted-by":"crossref","unstructured":"Lopalco A , Denora N . Paediatric Formulation: Design and Development. Int J Mol Sci 2020;21. doi:10.3390\/ijms21197118","DOI":"10.3390\/ijms21197118"},{"key":"2026051307251272000_16.5.e100150.7","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.180000"},{"key":"2026051307251272000_16.5.e100150.8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/oxrep\/grv039","article-title":"Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria","volume":"32","author":"Berdud","year":"2016","journal-title":"ECOPOL"},{"key":"2026051307251272000_16.5.e100150.9","unstructured":"UNITAID . UNITAID annual report 2010. Geneva UNITAID Secretariat, World Health Organisation; 2011. Available: https:\/\/unitaid.org\/assets\/UNITAID_AR2010_ENG.pdf"},{"key":"2026051307251272000_16.5.e100150.10","unstructured":"PHTI . Strategic Framework: Pediatric HIV Treatment Initiative (PHTI) - Accelerating Development of Paediatric ARV Formulations to Close the Treatment Gap [Internet]. Available: https:\/\/unitaid.org\/assets\/PHTI_Strategic_Framework_June_2016.pdf"},{"key":"2026051307251272000_16.5.e100150.11","unstructured":"Medicines for Malaria Venture (MMV) . WHO prequalification of coartem\u00ae baby marks breakthrough in treating malaria in newborns and young infants [Internet]. 2026. Available: https:\/\/www.mmv.org\/news-resources-search\/who-prequalification-coartemr-baby-marks-breakthrough-treating-malaria [Accessed 8 May 2026]."},{"key":"2026051307251272000_16.5.e100150.12","unstructured":"Global Accelerator for Paediatric Formulations (GAP-f) . Paediatric Drug Optimization for Neglected Tropical Diseases [Meeting Report] [Internet]. World Health Organization; 2023. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240085176"},{"key":"2026051307251272000_16.5.e100150.13","doi-asserted-by":"crossref","unstructured":"Premji ZG . Coartem: the journey to the clinic. Malar J 2009;8. doi:10.1186\/1475-2875-8-S1-S3","DOI":"10.1186\/1475-2875-8-S1-S3"},{"key":"2026051307251272000_16.5.e100150.14","doi-asserted-by":"crossref","unstructured":"Abdulla S , Sagara I . Dispersible formulation of artemether\/lumefantrine: specifically developed for infants and young children. Malar J 2009;8. doi:10.1186\/1475-2875-8-S1-S7","DOI":"10.1186\/1475-2875-8-S1-S7"},{"key":"2026051307251272000_16.5.e100150.15","unstructured":"Novartis. [Internet] . Novartis malaria treatment Coartem\u00ae Baby receives WHO prequalification, paving way for greater access for newborns and young infants, 2026. Available: https:\/\/www.novartis.com\/news\/media-releases\/novartis-malaria-treatment-coartem-baby-receives-who-prequalification-paving-way-greater-access-newborns-and-young-infants [Accessed 8 May 2026]."},{"key":"2026051307251272000_16.5.e100150.16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/cpt.1744","article-title":"Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap","volume":"107","author":"Goulooze","year":"2020","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026051307251272000_16.5.e100150.17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4269\/ajtmh.18-0649","article-title":"Strength in Numbers: The WWARN Case Study of Purpose-Driven Data Sharing","volume":"100","author":"Humphreys","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2026051307251272000_16.5.e100150.18","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.12259.1","article-title":"Sharing individual patient and parasite-level data through the WorldWide Antimalarial Resistance Network platform: A qualitative case study","volume":"2","author":"Pisani","year":"2017","journal-title":"Wellcome Open Res"},{"key":"2026051307251272000_16.5.e100150.19","unstructured":"Pisani E , Botchway S . Learning from the pioneers: lessons about data platforms drawn from the WorldWide Antimalarial Resistance Network (WWARN) experience. Wellcome Trust 2016. doi:10.6084\/m9.figshare.4476308.v2"},{"key":"2026051307251272000_16.5.e100150.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003019","article-title":"Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study","volume":"17","author":"Tierney","year":"2020","journal-title":"PLoS Med"},{"key":"2026051307251272000_16.5.e100150.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3656"},{"key":"2026051307251272000_16.5.e100150.22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0223","article-title":"Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children","volume":"138","author":"Pica","year":"2016","journal-title":"Pediatrics"},{"key":"2026051307251272000_16.5.e100150.23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jphys.2021.04.001","article-title":"Research Note: Individual participant data (IPD) meta-analysis","volume":"67","author":"Hayden","year":"2021","journal-title":"J Physiother"},{"key":"2026051307251272000_16.5.e100150.24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40272-014-0103-3","article-title":"Pediatric Clinical Drug Trials in Low-Income Countries: Key Ethical Issues","volume":"17","author":"MacLeod","year":"2015","journal-title":"Pediatr Drugs"},{"key":"2026051307251272000_16.5.e100150.25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S2352-4642(24)00210-4","article-title":"Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis","volume":"8","author":"Commons","year":"2024","journal-title":"The Lancet Child & Adolescent Health"},{"key":"2026051307251272000_16.5.e100150.26","doi-asserted-by":"crossref","unstructured":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group . The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. PLoS Med 2013;10. doi:10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371","DOI":"10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371"},{"key":"2026051307251272000_16.5.e100150.27","unstructured":"World Health Organization . Guidelines for the treatment of malaria. 3rd edn. Geneva: World Health Organization, Available: https:\/\/apps.who.int\/iris\/handle\/10665\/162441"},{"key":"2026051307251272000_16.5.e100150.28","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/S2214-109X(24)00003-2","article-title":"Does acute malnutrition in young children increase the risk of treatment failure following artemisinin-based combination therapy? A WWARN individual patient data meta-analysis","volume":"12","author":"Stepniewska","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026051307251272000_16.5.e100150.29","doi-asserted-by":"crossref","unstructured":"Das D , Grais RF , Okiro EA , et al . Complex interactions between malaria and malnutrition: a systematic literature review. BMC Med 2018;16. doi:10.1186\/s12916-018-1177-5","DOI":"10.1186\/s12916-018-1177-5"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:25:35Z","timestamp":1778682335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-100150"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100150","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}